Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=50137251-e620-4bf1-a619-754aac002bef
Date 8/11/2015
Company Name Sentien Biotechnologies
Mailing Address 196 Boston Avenue Medford, MA 02155 USA
Company Description Sentien has developed proprietary cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy.
Proceeds Purposes Sentien will use the proceeds of its Series A round to fund its activities through a planned Phase I study of their lead product, the Sentinel™, a cell-containing dialysis device for the treatment of Acute Kidney Injury (AKI).
M&A Terms
Venture Investor Boehringer Ingelheim Venture Fund